关闭
 
读者在线:用户名 密码
首页 期刊简介 投稿须知 期刊目录 专家风采 编委会 特邀顾问 联系我们 移动出版
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5



刊物信息

期刊名称:药物分析杂志
主管单位:中国科学技术协会
主办单位:中国药学会
承办:中国食品药品检定研究院
主编:金少鸿
地址:北京天坛西里2号
邮政编码:100050
电话:010-67012819,67058427
电子邮箱:ywfx@nicpbp.org.cn
国际标准刊号:ISSN 0254-1793
国内统一刊号:CN 11-2224/R
邮发代号:2-237
 

访问统计
您是第  2 9 1 2 5 1 8 位浏览者
您当前的位置:首页 >> 正文

HPLC法检测托吡司特中的基因毒性杂质对甲苯磺酸异丙酯、对甲苯磺酸仲丁酯、对甲苯磺酸乙酯

Determination of genotoxic impurities isopropyl p-toluensulfonate, sec-butyl p-toluenesulfonate and ethyl p-toluenesulfonate in topiroxostat by HPLC

作者: 谢卫锋, 高玉珍 
作者(英文):
分类号:R917
出版年·卷·期(页码):2018,38 (10):1788-1793
DOI: 10.16155/j.0254-1793.2017.01.01
-----摘要:-------------------------------------------------------------------------------------------

目的:建立一种高效液相色谱测定托吡司特的基因毒性杂质对甲苯磺酸异丙酯(杂质H)、对甲苯磺酸仲丁酯(杂质I)和对甲苯磺酸乙酯(杂质J)的方法。方法:采用C18色谱柱(100 mm×4.6 mm,3.5 μm),以水为流动相A,乙腈为流动相B,进行梯度洗脱,流速0.8 mL·min-1,检测波长220 nm,柱温40℃。结果:杂质H、I及J质量浓度分别在0.050~0.202 μg·mL-1R2=0.999 7)、0.048~0.192 μg·mL-1R2=0.999 8)及0.051~0.204 μg·mL-1R2=0.999 5)范围内与峰面积呈良好线性关系,定量下限分别为0.050 5、0.048 0和0.051 0 μg·mL-1,检测下限分别为0.016 7、0.015 8和0.016 8 μg·mL-1,平均回收率分别为99.3%(RSD=1.9%)、103.0%(RSD=1.2%)和98.2%(RSD=1.6%)。3批样品中均未检出基因毒性杂质H、I及J。结论:本法适用于托吡司特中的基因毒性杂质H、I及J的检测及限度控制。

-----英文摘要:---------------------------------------------------------------------------------------

Objective:To establish an HPLC method for the determination of genotoxic impurities isopropyl p-toluensulfonate(impurity H), sec-butyl p-toluenesulfonate(impurity I) and ethyl p-toluenesulfonate(impurity J) in topiroxostat.Methods:The method was achieved on a C18 column(100 mm×4.6 mm, 3.5 μm);the mobile phase consisted of water(A) -acetonitrile(B) with gradient elution at a flow rate of 0.8 mL·min-1;the detection wavelength was 220 nm, and the column temperature was 40℃.Results:Good linear relationships between the mass concentrations and the peak areas of impurities H, I, and J in the ranges of 0.050-0.202 μg·mL-1(R2=0.999 7), 0.048-0.192 μg·mL-1(R2=0.999 8), and 0.051-0.204 μg·mL-1(R2=0.999 5) were achieved.The limits of quantification were 0.050 5 μg·mL-1, 0.048 0 μg·mL-1 and 0.051 0 μg·mL-1, respectively.The limits of detection were 0.016 7 μg·mL-1, 0.015 8 μg·mL-1 and 0.016 8 μg·mL-1, respectively.The average recoveries were 99.3%(RSD=1.9%), 103.0%(RSD=1.2%) and 98.2%(RSD=1.6%), respectively.No genotoxic impurities H, I and J were detected in three batches of samples.Conclusion:This method is applicable to the detection and limit control of genotoxic impurities H, I, and J in topiramate.

-----参考文献:---------------------------------------------------------------------------------------
[1] 国家食品药品监督管理总局.国食药监注[2005] 106号化学药物杂质研究的技术指导原则[S].2005 State Food and Drug Administration.State Food and Drug Administration Note[2005] 106 Technical Guidelines for the Study of Chemical Impurities[S].2005
[2] 王萍,徐彩虹,陈仙,等.原料药中基因毒性杂质控制的研究进展[J].中国现代应用药学,2015,32(1):119 WANG P,XU CH,CHEN X,et al.Development of genotoxic impurities control in active pharmaceutical ingredient[J].Chin J Mod Appl Pharm,2015,32(1):119
[3] 张慧敏,林建群,冯康彪,等.药品中遗传毒性杂质的评估和控制[J].中国现代应用药学,2014,31(9):1160 ZHANG HM,LIN JQ,FENG KB,et al.Evaluation and control of genotoxic impurities in drugs[J].Chin Mod Appl Pharm,2014,31(9):1160
[4] EMA(European Medicines Agency).Guidelines on the Limits of Genotoxic Impurities[EB/OL].(2006-06-28)[2017-08-20].http://www.EMA.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002903.pdf
[5] European Directorate for the Quality of Medicines and Health Care.Enquiry:Alkyl mesilate(methane sulfonate)impurities in mesilate salts[J].Pharm Europa,2000,12(1):27
[6] Committee for Proprietary Medicinal Products.Position Paper on the Limits of Genotoxic Impurities[S].2002
[7] European Medicines Agency.EMEA/CHMP/SWP/431994/2007 Pre-authorization Evaluation of Medicines for Human Use,Question&answers on the CHMP Guideline on the Limits of Genotoxic Impurities[S].2008
[8] 张芳芳,朱心强.新药中遗传毒性杂质及其管理[J].浙江预防医学,2007,19(12):65 ZHANG FF,ZHU XQ.Genotoxicity in new drugs and its management[J].Zhejiang J Prev Med,2007,19(12):65
[9] 宋冬梅,徐倩昱,任美婷,等.HPLC-Q TOF MS法测定马来酸依那普利及中间体中的对甲苯磺酸乙酯[J].药物分析杂志,2012,32(5):834 SONG DM,XU QY,REN MT,et al.Determination of ethyl p-toluenesulfonate in enalapril maleate and its intermediates by HPLC-Q TOF MS[J].Chin J Pharm Anal,2012,32(5):834
[10] U.S.Department of Health and Human Services Food and Drug Administration.Guidance for Industry.Genotoxic and Carcinogenic Impurities in Drug Substances and Products:Recommended Approaches(Draft guideline)[S].2008
[11] KROES R,RENWICK AG,CHEESEMAN M,et al.Structure-based thresholds of toxicological concern(TTC):guidance for application to substances present at low levels in the diet[J].Food Chem Toxicol,2004,42(1):65
[12] MULLER L,MAUTHE RJ,RILEY CM,et al.A rationale for determination,testing and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity[J].Regul Toxicol Pharmacol,2006,44(3):198
[13] 张园园,李银峰,王杰晶,等.药物中痕量磺酸酯类物质的检测技术研究进展[J].药物评价研究,2012,35(4):304 ZHANG YY,LI YF,WANG JJ,et al.Research progress in detection technology of trace sulfonate in drugs[J].Drug Eval Res,2012,35(4):304
[14] 孙朴.HPLC法测定氢溴酸西酞普兰中的基因毒性杂质对甲苯磺酸乙酯[J].药学研究,2015,34(11):637 SUN P.Determination of genotoxic impurities p-toluenesulfonate in citalopram hydrobromide by HPLC[J].J Pharm Res,2012,35(4):304
[15] 马磊,马玉楠,陈震,等.遗传毒性杂质的警示结构[J].中国新药杂志,2014,23(18):2106 MA L,MA YN,CHEN Z,et al.Warning structure of genotoxic impurities[J].Chin J New Drugs,2014,23(18):2106

欢迎阅读《药物分析杂志》!您是该文第 58位读者!

药物分析杂志 © 2009
地址:北京天坛西里2号
邮政编码:100050; 技术支持:010-60213898

电子邮件:ywfx@nicpbp.org.cn